|本期目录/Table of Contents|

[1]张骏飞,郭远,陈从新,等.替比夫定治疗慢加亚急性乙型肝炎肝衰竭的疗效观察[J].医学研究与战创伤救治(原医学研究生学报),2016,18(02):131-134.[doi:10.3969/j.issn.1672-271X.2016.02.007]
　ZHANG Jun-fei,GUO Yuan,CHEN Cong-xin,et al.A study on the treatment effect of telbivudine on hepatitis B patients with acute on chronic liver failure[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2016,18(02):131-134.[doi:10.3969/j.issn.1672-271X.2016.02.007]
点击复制

替比夫定治疗慢加亚急性乙型肝炎肝衰竭的疗效观察()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第18卷
期数:
2016年02期
页码:
131-134
栏目:
出版日期:
2016-04-09

文章信息/Info

Title:
A study on the treatment effect of telbivudine on hepatitis B patients with acute on chronic liver failure
作者:
张骏飞; 郭远; 陈从新; 宋海燕; 董静; 陈曦; 陈照林; 刘波
230031 安徽合肥，解放军105医院感染病科
Author(s):
ZHANG Jun-fei;  GUO Yuan;  CHEN Cong-xin;  SONG Hai-yan;  DONG Jing;  CHEN Xi;  CHEN Zhao-lin;  LIU Bo．
Department of Infectious Diseases， 105 Hospital of PLA， Hefei, Anhui 230031， China
关键词:
替比夫定; 拉米夫定; 乙型肝炎; 肝衰竭
Keywords:
telbivudine;  lamivudine;  hepatitis B;  hepatic failure
分类号:
R512.62
DOI:
10.3969/j.issn.1672-271X.2016.02.007
文献标志码:
A
摘要:
目的 探讨替比夫定治疗慢加亚急性乙型肝炎肝衰竭患者104周的临床疗效和基因变异情况。方法 共纳入80例慢加亚急性乙型肝炎肝衰竭患者，治疗组41例，对照组 39例，分别在常规治疗的基础上使用替比夫定、拉米夫定治疗，每3～6个月进行HBV DNA、ALT、TBIL、INR及HBeAg检测，判断疗效。结果 在治疗52周和104周时，治疗组HBeAg转阴 率分别是54.2%和62.5%,与对照组HBeAg转阴率和转换率16.0%和20.0%比较差异有统计学意义(P<0.05)。结论 替比夫定能够迅速抑制HBV复制，HBeAg血清学转阴率和转换率高，能阻 断病情发展,适合慢加亚急性乙型肝炎肝衰竭患者治疗。
Abstract:
Objective We conducted a pilot clinical trial to observe the efficacy of telbivudine in the treatment of hepatitis B patients with acute on chronic liver failure. Methods We randomly divided hepatitis B patients with acute on chronic liver failure into two groups. One group (n=41) was treated with telbivudine for two years, while the other (n=39) with lamivudine for two years. HBV DNA, ALT, TBIL, INR and HBeAg level of these patients were tested every 3-6 months. Results During a total of 104 treatment weeks, there were no significant difference in the change of the leves of ALT, TBIL, INR and the motality rate. However, the loss and seroconversion rate of HBeAg at week 52 week and 104 week were significantly higher in the telbivudine group than in the lamivudine group(54.2% vs 16.0%, 62.5% vs 20.0%, P<0.05). Conclusion Telbivudine has an strong anti-HBV activity and a rapid effect. It can block the disease development for hepatitis B patients with liver failure.

参考文献/References:

[1]谢 芳，汪茂荣，张 馨,等. 替比夫定联合胸腺素-α1与单用替比夫定治疗HBeAg阳性慢性乙型肝炎的比较研究[J].东南国防医药，2015，17(4):342：342-345.
[2]中华医学会感染病学分会肝功能衰竭与人工肝学组，中华医学会肝病学分会重型肝病与人工肝学组．肝功能衰竭诊治指南[J].实用肝脏病杂志，2013，16（3）：210-216.
[3]郭晓凤，施军平，武 静，等．74例经拉米夫定治疗的乙型肝炎病毒感染者耐药情况分析[J]．中华临床感染病杂志，2012，5(5)：286-288．
[4]Enqiang C，Lang B,Lanlan C, et al. Prolonged combination therapy is more efective than monotherapy in management of chronic hepatitis B patients with sustained virological response: an experience from a ‘real-world’ clinical setting[J].Iran Red Crescent Med J, 2013，15(12): e7788.
[5]Liaw YE,Gane E,Leung N,et al.2-year GLOBE trial result:telbivudine is superior to lamivdine in patients with chronic hepatitis B [J].Gastroneterology,2009,136(2):486-495.
[6]Evans A，Riva A，Cooksley H，et al．Programmed death 1 expression during antiviral treatment of chronic hepatitis B：impact of hepatitis B e-antigen seroconversion[J]．Hepatology，2008，48：759-769.
[7]黄鸿菲，何登明，王宇明，等. HBeAg阳性慢性乙型肝炎孕妇替比夫定治疗前后血清Th1/Th2型细胞因子的水平变化[J]．临床肝胆病杂志，2014，30(6):522-526.
[8]安宝燕，蔡 伟，谢 青,等.替比夫定与恩替卡韦治疗HBeAg阳性慢性乙型肝炎患者的疗效及其影响因素[J].肝脏，2013,18（4）：220-222.
[9]Dai M,Xiao GM,Wang FL,et al.Changes in serum alanine aminotransferase levels in telbivudine versus lamivudine treatment for chronic hepatitis B:a meta- analysis[J].J Int Med Res, 2015，43(2):161-172.
[10]Sun J,Xia Q,Tan D.et al.The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: a randomized, controlled study[J]. Hepatology, 2014，59(4):1283-92.
[11]汪茂荣. 解读《2008亚太肝病研究学会慢性乙型肝炎防治指南》[J].东南国防医药杂志，2008,10（4）：241-242.

相似文献/References:

[1]谢 芳,汪茂荣,张 馨,等.替比夫定联合胸腺素-α1与单用替比夫定治疗HBeAg阳性慢性乙型肝炎的比较研究[J].医学研究与战创伤救治(原医学研究生学报),2015,17(04):342.[doi:10.3969/j.issn.1672-271X.2015.04.002]
　XIE Fang,WANG Mao-rong,ZHANG Xin,et al.Telbivudine (LDT) compared with LDT plus thymosin-α1 for treatment of HBeAg-positive chronic hepatitis B[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(02):342.[doi:10.3969/j.issn.1672-271X.2015.04.002]

备注/Memo

备注/Memo:
解放军105医院院管课题项目（10Y915）
更新日期/Last Update: 2016-03-20